This Year’s Flu Shot Has Been Updated After a Tough Flu Season. Here’s What You Should Know

If you haven’t gotten your flu shot yet this fall, there’s still time to protect yourself before influenza season reaches its peak.

And this year’s vaccine has something important going for it: Scientists have updated all three of its influenza components, including one designed to better match the virus responsible for much of last winter’s flu activity.

That change follows a difficult 2025–2026 flu season, when a rapidly spreading influenza A variant caused widespread illness and sent hundreds of thousands of Americans to hospitals.

The problem wasn’t simply that last year’s vaccine was poorly designed. A new version of the virus emerged after scientists had already selected the strains manufacturers would use.

By the time the variant became widespread, millions of vaccine doses were already being produced.

Why Last Year’s Flu Vaccine Faced a Challenge

Making a seasonal influenza vaccine requires scientists to predict which viruses are most likely to circulate months before the shots reach pharmacies and doctors’ offices.

The process begins with an international review of influenza surveillance data.

Scientists study flu viruses circulating worldwide, looking for genetic changes and signs that certain strains are becoming more common.

Recommendations for the Northern Hemisphere’s 2025–2026 vaccines were made in February 2025, with U.S. selections finalized in March.

But influenza viruses are constantly changing.

In summer 2025, scientists identified a new variant of influenza A(H3N2), known as subclade K.

The variant had acquired genetic changes that made it different from the H3N2 virus selected for that season’s vaccine.

Those differences matter because the immune system learns to recognize particular features on a virus’s surface.

When those features change, antibodies produced after vaccination may not recognize the new virus as effectively.

Scientists call this process antigenic drift.

By the time the 2025–2026 flu season was underway, subclade K had become the dominant H3N2 variant in the United States.

A Difficult Season, Especially for Children

According to the Centers for Disease Control and Prevention, approximately 93% of the H3N2 virus samples genetically characterized during the season’s surveillance period belonged to subclade K.

The variant contributed to a particularly difficult flu season.

Researchers reported that the cumulative rate of flu-related hospitalizations was the third-highest recorded since the 2010–2011 season.

Among children younger than 18, the hospitalization rate was the second-highest during that period.

Older adults were also heavily affected, as influenza A(H3N2) seasons have historically been associated with substantial illness and hospitalization among people 65 and older.

The mismatch between the vaccine’s H3N2 component and the circulating variant likely reduced protection against some infections.

However, that does not mean last year’s vaccine was useless.

CDC research found that vaccination still offered protection against influenza-related medical visits and hospitalizations.

The lesson for researchers was that predicting how flu viruses will change remains one of the biggest challenges in designing an effective seasonal vaccine.

What’s Different About the 2026–2027 Flu Shot?

For the current flu season, the Food and Drug Administration recommended updating all three virus components included in U.S. influenza vaccines.

Those components target:

• Influenza A(H1N1)
• Influenza A(H3N2)
• Influenza B, Victoria lineage

The updated H3N2 component was selected to better match subclade K and related viruses.

The other two components were also changed to reflect more recent circulating strains.

Last season, only the H3N2 component had been updated from the previous year’s vaccine.

These changes reflect what scientists learned from the viruses that circulated during the 2025–2026 season.

But there is an important limitation.

The updated vaccine is designed around the viruses researchers expect to circulate. It cannot guarantee protection against every strain that might emerge.

Influenza continues to evolve, and vaccine effectiveness will depend partly on how closely circulating viruses match the selected components.

Why September and October Are Usually Recommended

The CDC generally recommends that most people receive their annual influenza vaccination during September or October.

The timing is deliberate.

Flu activity typically begins increasing in the fall, but illness levels usually peak between December and February.

Getting vaccinated in early fall gives the immune system time to develop protection before the virus becomes widespread.

It also helps avoid another problem: declining immunity.

Protection from a flu shot can decrease gradually over several months.

That is one reason health officials generally advise most adults, particularly those 65 and older, not to get vaccinated as early as July or August unless they are concerned they might not be able to receive the vaccine later.

The goal is to have meaningful protection during the months when influenza is most likely to circulate.

Is November Too Late for a Flu Shot?

Not at all.

Although October is generally considered ideal, the CDC recommends continuing influenza vaccination after October as long as flu viruses are circulating and vaccines remain available.

If you get a flu shot in early November, you still have time to build protection before the busiest part of flu season.

According to the CDC, it takes approximately two weeks after vaccination for protective antibodies to develop.

That means someone vaccinated in early November can generally expect to have developed an immune response before Thanksgiving gatherings later in the month.

The vaccine does not provide immediate protection, however, and it cannot guarantee that someone will not get influenza.

Even so, vaccination can lower the risk of illness and serious complications.

Who Should Get Vaccinated?

The CDC’s current guidance recommends annual influenza vaccination for nearly everyone 6 months of age and older, with rare exceptions.

Vaccination is particularly important for people at greater risk of serious flu complications, including older adults, pregnant women, young children, and people with certain chronic medical conditions.

For adults 65 and older, the CDC preferentially recommends certain vaccines, including high-dose, recombinant, or adjuvanted influenza vaccines, when available.

Some children between 6 months and 8 years old may need two doses, depending on their previous vaccination history.

If you have questions about which vaccine is appropriate, consult a pharmacist or healthcare provider.

Flu Prevention Doesn’t End With Vaccination

While vaccination remains a major tool for reducing influenza-related illness, other precautions can help limit the spread of respiratory infections.

Washing hands regularly, covering coughs and sneezes, improving indoor air circulation, and avoiding close contact with others when sick can help reduce transmission.

People at increased risk of complications should also contact their healthcare provider promptly if they develop flu symptoms.

Prescription antiviral medications can help treat influenza, particularly when started early in the illness.

For some people, treatment may reduce the risk of severe complications.

A Better Match, but Not a Guarantee

The emergence of subclade K during the last flu season demonstrates why influenza vaccines must be evaluated and updated every year.

Scientists made their 2025 vaccine selections using the information available at the time. The virus changed afterward.

This year’s vaccine has been adjusted to account for those developments.

Whether it provides substantially better protection will become clearer as researchers study how well the vaccine performs against the viruses circulating during the 2026–2027 season.

For now, health officials emphasize a practical point.

It’s early November, and the period when flu activity usually peaks is still ahead.

For people who haven’t been vaccinated, there is still an opportunity to get protection in place before winter.